本文選題：心肌梗死 + 尿激酶型纖溶酶原激活物��； 參考：《中國(guó)全科醫(yī)學(xué)》2016年17期

【摘要】：目的探討國(guó)產(chǎn)重組人尿激酶原治療急性心肌梗死(AMI)的有效性和安全性。方法計(jì)算機(jī)檢索Pub Med、EMBase、Cochrane Library、中國(guó)知網(wǎng)、維普網(wǎng)、萬(wàn)方數(shù)據(jù)知識(shí)服務(wù)平臺(tái)等數(shù)據(jù)庫(kù)中已發(fā)表的觀察國(guó)產(chǎn)重組人尿激酶原治療AMI安全性和有效性的文獻(xiàn),時(shí)間限定為建庫(kù)至2015年9月。由兩名評(píng)價(jià)員獨(dú)立進(jìn)行文獻(xiàn)篩選和質(zhì)量評(píng)價(jià),按預(yù)先設(shè)計(jì)的表格提取資料,包括第一作者、發(fā)表時(shí)間、治療時(shí)間、年齡、樣本量、劑量及評(píng)價(jià)指標(biāo)。納入文獻(xiàn)首先進(jìn)行異質(zhì)性分析,分類(lèi)變量采用比值比(OR值)及其95%CI為合并效應(yīng)量。結(jié)果共納入10篇文獻(xiàn),AMI患者875例,方法學(xué)質(zhì)量評(píng)價(jià)均為B級(jí)。國(guó)產(chǎn)重組人尿激酶原治療AMI患者再通率〔OR=2.63,95%CI(1.95,3.54)〕、完全再通率〔OR=2.85,95%CI(2.09,3.89)〕高于尿激酶,30 d主要不良心血管事件(MACE)發(fā)生率〔OR=0.42,95%CI(0.27,0.65)〕、輕微出血發(fā)生率〔OR=0.52,95%CI(0.33,0.81)〕、出血發(fā)生率〔OR=0.41,95%CI(0.28,0.62)〕低于尿激酶,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。國(guó)產(chǎn)重組人尿激酶原與尿激酶治療AMI患者嚴(yán)重出血發(fā)生率比較,差異無(wú)統(tǒng)計(jì)學(xué)意義〔OR=0.24,95%CI(0.05,1.12),P=0.07〕。結(jié)論與尿激酶相比,國(guó)產(chǎn)重組人尿激酶原治療AMI患者血管再通率高,MACE發(fā)生率低,出血并發(fā)癥少。
[Abstract]:Objective to evaluate the efficacy and safety of domestic recombinant human urokinase in the treatment of acute myocardial infarction (AMI). Methods A computer search was carried out to search the published literatures on the safety and efficacy of domestic recombinant human urokinase in the database of Pub Medsite, China knowledge Network, Wiplnet and Wanfang data knowledge Service platform for the treatment of AMI. The time limit was to build the database until September 2015. Literature screening and quality evaluation were carried out independently by two evaluators, and the data were extracted according to pre-designed tables, including the first author, time of publication, time of treatment, age, sample size, dose and evaluation index. In the literature, the heterogeneity was analyzed first, and the ratio or (OR) and its 95%CI were used as the combined effect. Results A total of 875 patients with AMI were included in 10 articles. The rate of recanalization of patients with AMI treated by domestic recombinant human urokinase was 1.955 / 3.54 and the rate of complete recanalization was 2.859 / 95 respectively), which was higher than that of urokinase / urokinase for 30 days, the incidence of major adverse cardiovascular events was higher than that of OR0.4295CI0.270.650.The incidence of slight hemorrhage was 0.330.81. The incidence of hemorrhage was lower than that of urokinase (P 0.05). There was no significant difference in the incidence of severe hemorrhage between domestic recombinant human urokinase and urokinase in AMI patients. Conclusion compared with urokinase, the rate of vascular recanalization in patients with AMI treated by domestic recombinant human urokinase is higher than that of urokinase, and the incidence of Mace is lower and the complication of bleeding is less.
【作者單位】： 河北醫(yī)科大學(xué)第二醫(yī)院心血管內(nèi)科;
【分類(lèi)號(hào)】：R542.22

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 向萌;顧燕黎;趙鳳娣;殷蓮華;;重組人尿激酶原病毒安全性研究[J];中國(guó)新藥雜志;2006年05期

2 趙專(zhuān)友,劉蓓鈁,劉厚孝,孫自勇,張菁,劉建寧;重組人尿激酶原藥效學(xué)研究[J];南京大學(xué)學(xué)報(bào)(自然科學(xué)版);2001年04期

3 高麗華;張正光;胡顯文;胥照平;肖成祖;郗永義;邵勇;;重組人尿激酶原凍干產(chǎn)品的穩(wěn)定性[J];生物技術(shù)通訊;2008年03期

4 陶銅靜;袁婀娜;楊旭;將琴;李小強(qiáng);李世崇;高麗華;胡顯文;胥照平;張正光;;用高效液相色譜測(cè)定重組人尿激酶原制劑的蛋白含量[J];生物技術(shù)通訊;2010年01期

5 張正光;;重組人尿激酶原的臨床研究概況[J];生物技術(shù)通訊;2012年02期

6 方泰慧,張菁,張培祥,朱德煦,徐立,劉建寧,劉蓓鈁;重組人尿激酶原一般藥理學(xué)研究[J];南京大學(xué)學(xué)報(bào)(自然科學(xué)版);2001年04期

7 寧榮霞;王瑞;崔曉迎;;新型溶栓藥物重組人尿激酶原[J];中國(guó)新藥雜志;2008年05期

8 丁有學(xué);李響;韓春梅;饒春明;王軍志;;重組人尿激酶原質(zhì)控方法和質(zhì)量標(biāo)準(zhǔn)的研究[J];中國(guó)生物制品學(xué)雜志;2007年07期

9 尿激酶原臨床試驗(yàn)協(xié)作組;李天德;肖成祖;劉銳;劉麗鳳;;重組人尿激酶原治療急性ST段抬高性心肌梗死的多中心Ⅲ期臨床試驗(yàn)[J];醫(yī)學(xué)研究雜志;2013年10期

10 劉闖,張金盈,黃振文,李華,邱春光,黨瑜華,趙洛莎,張彥周,張曉,張慧琴,劉保山;國(guó)產(chǎn)注射用重組人尿激酶原治療急性心肌梗死療效觀察[J];鄭州大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2004年06期

相關(guān)會(huì)議論文 前2條

1 陳錚;;重組人尿激酶原研究進(jìn)展[A];第十屆沈陽(yáng)科學(xué)學(xué)術(shù)年會(huì)論文集（農(nóng)業(yè)科學(xué)與醫(yī)藥科學(xué)分冊(cè)）[C];2013年

2 方泰惠;張培祥;徐立;羅炳輝;楊世華;陳于紅;張菁;劉建寧;;重組人尿激酶原(pro-UK)的長(zhǎng)期毒性[A];中國(guó)藥理學(xué)會(huì)第八屆全國(guó)藥物毒理學(xué)術(shù)討論會(huì)論文摘要集[C];2001年

相關(guān)重要報(bào)紙文章 前2條

1 悅己;國(guó)家一類(lèi)生物新藥普佑克臨床療效顯著[N];中國(guó)醫(yī)藥報(bào);2014年

2 顧雷鳴;發(fā)揮開(kāi)放型經(jīng)濟(jì)發(fā)展優(yōu)勢(shì) 下更大功夫推進(jìn)自主創(chuàng)新[N];新華日?qǐng)?bào);2006年

相關(guān)碩士學(xué)位論文 前1條

1 寧榮霞;注射用重組人尿激酶原溶栓治療急性心肌梗死的臨床研究[D];內(nèi)蒙古醫(yī)學(xué)院;2006年

，

本文編號(hào)：1874961